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Nobuyuki Kato,e Roland M. Schmid,a Asit K. Pattnaik,b and Oliver Eberta
Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germanya; School of Veterinary Medicine and Biomedical Sciences and the
Nebraska Center for Virology, University of Nebraska—Lincoln, Lincoln, Nebraska, USAb; Department of Medicine 2, University Hospital Grosshadern, University of Munich,
Munich, Germanyc; Department of Traumatology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germanyd; and Department of Molecular Biology,
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japane

Vesicular stomatitis virus (VSV), a negative-sense single-stranded-RNA rhabdovirus, is an extremely promising oncolytic agent
for cancer treatment. Since oncolytic virotherapy is moving closer to clinical application, potentially synergistic combinations of
oncolytic viruses and molecularly targeted antitumor agents are becoming a meaningful strategy for cancer treatment. Mitogenactivated protein kinase (MAPK) inhibitors have been shown to impair liver cell proliferation and tumor development, suggesting their potential use as therapeutic agents for hepatocellular carcinoma (HCC). In this work, we show that the impairment of
MAPK in vitro did not interfere with the oncolytic properties of VSV in HCC cell lines. Moreover, the administration of MAPK
inhibitors did not restore the responsiveness of HCC cells to alpha/beta interferon (IFN-␣/␤). In contrast to previous reports, we
show that JNK inhibition by the inhibitor SP600125 is not responsible for VSV attenuation in HCC cells and that this compound
acts by causing a posttranslational modification of the viral glycoprotein.

V

esicular stomatitis virus (VSV), a negative-sense singlestranded-RNA rhabdovirus, which has inherent tumor specificity for replication due to attenuated type I interferon (IFN)
(IFN-␣/␤) responses in most tumor cells, is an extremely promising oncolytic agent for cancer treatment (52, 53). A characterization of cellular events supporting VSV oncolysis is important
for an understanding of virus-cell interactions in infected tumor
cells, including hepatocellular carcinoma (HCC). Moreover, an
investigation of the host cell determinants of permissiveness to
VSV infection is essential for the development of viral vectors with
enhanced oncolytic properties for HCC.
The c-Jun N-terminal kinases (JNKs) belong to the superfamily of mitogen-activated protein kinases (MAPKs), which also includes p38 MAPK and extracellular signal-regulated kinase (ERK)
(57). MAPKs are usually involved in the regulation of cell proliferation, differentiation, and apoptosis (6, 28). JNKs are activated,
together with p38 MAPK, by different stimuli, including stress
factors, inflammatory cytokines, and cytotoxic and genotoxic factors and play a critical role in mediating apoptotic signaling (32).
JNK and p38 MAPK signals are often deregulated during malignant transformation, and cancer cells can subvert these pathways
to facilitate proliferation, survival, and invasion (4, 5, 17, 24). JNK
has been reported to exert oncogenic functions in HCC, and an
increased kinase activity correlates with increased tumor proliferation (8, 22). The inhibition of JNK has been shown to impair liver
cell proliferation and tumor development, suggesting the potential use of these inhibitors as therapeutic agents for HCC (42).
Human HCC cells are highly resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cytotoxicity (51). Interestingly, treatment with a JNK inhibitor (JNKi)
(SP600125) sensitizes HCC cells to TRAIL, providing evidence
that the activity of JNK is required for resistance to apoptosis in
these tumors (41). Several members of different viral families ac-

tivate JNK and p38 MAPK gene-regulated cascades, in some cases
resulting in the induction of apoptosis in infected cells and increased viral replication (9, 18). In particular, the activation of the
JNK transduction pathway has been observed during infection
with several DNA and RNA viruses, suggesting an important role
in viral replication (2, 7, 10, 19). Interestingly, JNK activation is a
common feature of many disparate viruses; therefore, it may represent an important target for the development of antiviral treatments. The aberrant activation of JNK is an important feature of
tumorigenesis, and the constitutive activation of JNK occurs in
most HCCs. Since VSV is a promising therapeutic agent against
HCC, here we were interested in investigating the role of JNK in
VSV oncolysis. Our studies revealed that JNK inhibition by the
inhibitor SP600125 does not play any role in the attenuation of
VSV in HCC cells. Rather, this compound acts by inducing a posttranslational modification of the viral glycoprotein, resulting in a
significant reduction in the infectivity of the virus in these cells.
MATERIALS AND METHODS
Cell lines, primary human hepatocytes, and viruses. Two human HCC
cell lines (HepG2 and Huh-7), kind gifts from Ulrich Lauer (University
Hospital of Tübingen), were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1%
L-glutamine (200 mM), 1% penicillin-streptomycin, 1% nonessential
amino acids, and 1% sodium pyruvate. Immortalized human hepatocytes
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(PH5CH8) were maintained in DMEM–F-12 medium. All cell cultures
were regularly tested for mycoplasma contamination. Primary human
hepatocytes (PHH) were derived from patients (negative for hepatitis B
virus [HBV], hepatitis C virus [HCV], and HIV) who underwent surgical
resections of liver tumors. Human hepatocytes were isolated by a two-step
collagenase perfusion technique followed by Percoll gradient centrifugation for purification, as previously described (44). Wild-type VSV-green
fluorescent protein (GFP) was generated as previously described (14).
Virus stocks were produced on BHK-21 cells and stored at ⫺80°C. Titers
were determined by a plaque assay on BHK-21 cells (14).
Western blotting. Whole-cell extracts or isolated viral pellets were run
on a 7.5% SDS-PAGE gel and transferred onto nitrocellulose membranes.
Total cell lysates were prepared by using Cell Lysing buffer (Cell Signaling
Technology Inc., Danvers, MA) containing a protease and phosphatase
inhibitor cocktail. The protein concentration in the samples was determined by using a bicinchoninic acid (BCA) protein assay kit (Promega,
Madison, WI) according to the manufacturer’s instructions. After blocking for 1 h with 5% skim milk–Tris-buffered saline (TBS)–Tween, membranes were blotted with the following primary antibodies (Abs) overnight at 4°C: antibodies against basal and phosphorylated forms of JNK,
ERK1 and -2, and p38 MAPK (Cell Signaling); VSV-G (Abcam, Cambridge, United Kingdom); and actin (Sigma-Aldrich, Munich, Germany)
and anti-VSV serum (kindly provided by Douglas Lyles). After secondary
staining with anti-rabbit or anti-mouse peroxidase-conjugated Abs (Jackson ImmunoResearch Laboratories Inc., West Grove, PA), protein bands
were visualized on Amersham Hyper-Max film with the ECL chemiluminescence kit as recommended by the manufacturer (Amersham, Buckinghamshire, United Kingdom).
Viral growth assays. Single infections and one-step growth curves of
recombinant VSV (rVSV)-GFP were performed on PHH, immortalized
human hepatocytes (PH5CH8), and the HepG2 and Huh-7 cell lines.
Cells were infected at a multiplicity of infection (MOI) of 0.1 or 10 according to the experiment. After adsorption for 1 h, the monolayers were
washed three times with phosphate-buffered saline (PBS), and fresh medium was added. Aliquots of culture media were collected at the indicated
times postinfection. Viral titers were determined by 50% tissue culture
infective dose (TCID50) analysis and represent the averages of data from
triplicate experiments. For interferon protection assays, cells were mock
treated or incubated with 1,000 IU/ml of universal type I IFN (PBL Biomedical Laboratories) overnight and subsequently infected with rVSVGFP for 16 h.
Treatment with MAPK inhibitors, DTT, and urea. Cells were seeded
at 80 to 90% confluence in 24-well plates overnight. The next morning, the
culture media were replaced with fresh media containing dimethyl sulfoxide
(DMSO) or MAPK inhibitors at the indicated concentrations. After pretreatment for 16 h, virus infections were carried out in the presence of freshly
added inhibitors. Chemicals (SB203580 [10 M], SP600125 [25 M], and
U0126 [10 M]) were purchased from Calbiochem-Merck (Gibbstown, NJ).
For experiments with the JNK inhibitor, Huh-7 cells were pretreated with
SP600125 (25 M), and infection was allowed to proceed either in the absence or in the presence of fresh inhibitor for the entire duration of the experiment. Viral titers were determined at 24 h postinfection (hpi) by TCID50
analysis.
Dithiothreitol (DTT) was added to semipurified virions to final concentrations of 10 and 50 mM. Samples were incubated at 56°C for 15 min.
Treatment with urea was performed by the incubation of virions with 8 M
urea for 10 min at room temperature (RT); direct separation on SDSPAGE gels was applied without preheating the samples.
For the chemical cross-linking of VSV, samples of semipurified
virions were incubated with SP600125 to a final concentration of 25 M
for 1 h on ice. Alternatively, cross-linking with 2% paraformaldehyde
(PFA) was carried out on ice for 15 min. Samples were preheated at 56°C
for 10 min and assayed by Western blotting.
Real-time PCR. Cells were infected with rVSV-GFP; cell supernatants
and cell lysates were collected at the indicated time points. Cell debris was
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eliminated by centrifugation and total RNA was extracted, according to
the manufacturers’ instructions, by using the High Pure viral RNA kit
(Roche, Mannheim, Germany) and the RNeasy Plus minikit (Qiagen,
Valencia, CA), respectively. The forward and reverse primers generating a
138-nucleotide DNA fragment spanning one intergenic region between
the N and P genes were designed as previously reported (14). Quantitative
real-time PCR was carried out with the QuantiTect Probe reverse transcription kit (Qiagen, Valencia, CA) and the Kapa SYBR Fast qPCR Fast
LightCycler 480 kit (PeqLab, Erlangen, Germany), using 15 ng of the
template. The relative values for mRNA extracted from cell lysates were
quantified by normalizing the expression level of the gene of interest to the
level of the internal housekeeping control RNA (glyceraldehyde-3-phosphate dehydrogenase [GAPDH]). The quantification of viral RNA from
infected supernatants was performed by using an external standard curve.
siRNA assays. For small interfering RNA (siRNA) experiments, reverse transfection was performed by using Lipofectamine RNAiMax (Invitrogen). Cells in 24-well plates were transfected with either 100 nM
scrambled siRNA or specific siRNA (100 nM) according to the manufacturer’s instructions. siRNAs were synthesized by Dharmacon (Thermo
Fisher Scientific). After 48 to 72 h posttransfection, cultures were infected
with rVSV-GFP at an MOI of 0.1 for 16 h. Titers were determined as the
TCID50. Cell lysates from uninfected duplicate cultures were analyzed by
Western blotting to assess the efficiency of RNA silencing against JNK
expression. Alternatively, 48 h after siRNA transfection, cells were treated
with SP600125 or with DMSO and subsequently infected with VSV at an
MOI of 0.1.
Transfection of a VSV glycoprotein-encoding plasmid and evaluation of syncytium formation. The VSV-G expression plasmid (pCMVVSV-G) was kindly provided by Dorothee von Laer, Innsbruck, Austria.
One microgram of plasmid was transfected into Huh-7 cells by using
Lipofectamine LTX according to the manufacturer’s instructions (Invitrogen). At 8 h posttransfection, the supernatant was replaced with fresh
medium containing DMSO or SP600125 (25 M). GFP under the control
of a cytomegalovirus (CMV) promoter (pCMV-C3) was used as the transfection control. The presence of SP600125 did not influence transfection
efficiency rates, as observed by the level of GFP expression and the number
of GFP-positive cells with or without the inhibitor. Cell-cell fusion was
allowed to progress without low-pH treatment to activate fusion, as previously described (11, 48).
After 24 to 36 h, cells were fixed with ice-cold 70% ethanol for 5 to 10
min at ⫺20°C, and nuclei were visualized by propidium iodide staining.
Syncytium formation was determined by the syncytium index (SI), calculated as the number of nuclei per syncytium divided by the number of
nuclei per field of view. ImageJ software (National Institutes of Health,
Bethesda, MD) was used to quantify the number of nuclei.
Glycosylation analysis. Semipurified virions obtained from DMSO- or
SP600125-treated cells were subjected to digestion with endoglycosidase F
(PNGase F) or with endo-␣-N-acetylgalactosaminidase (EndoGalNAcase)
(New England BioLabs, Frankfurt am Main, Germany). Samples were incubated overnight at 37°C, according to the manufacturer’s instructions. Negative-control experiments were performed with deglycosylation buffers in the
absence of the respective deglycosylation enzymes.
Mass spectrometry of the modified VSV G protein. Purified VSV
obtained from SP600125-treated cells was separated on an SDS-PAGE gel.
Viral proteins were stained with the Coomassie staining method, using
GelCode Blue Stain reagent (Thermo Scientific) according to the manufacturer’s instructions. Selected bands were excised and subjected to liquid chromatography (LC)/mass spectrometry (MS) as described previously (26). Briefly, gel pieces were digested with trypsin (catalog no.
V5111; Promega, Madison, WI), and the digested peptides were extracted
in 5% formic acid–50% acetonitrile and separated by using a C18 reversedphase LC column (Milford, MA). A Q-TOF Ultima tandem mass spectrometer coupled with a Nanoaquity high-performance liquid chromatography (HPLC) system (Waters) with electrospray ionization was used
to analyze the eluting peptides. The peak lists of tandem mass spectrom-
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etry (MS/MS) data were generated by using Distiller (Matrix Science,
London, United Kingdom), using charge state recognition and deisotoping with the other default parameters for Q-TOF data. Database
searches of the acquired MS/MS spectra using NCBI database 20100701
were performed with Mascot (v2.2.0; Matrix Science, London, United
Kingdom). Mass accuracy settings were 0.15 Da for peptide masses and
0.12 Da for fragment ion masses.
Statistical analysis. Data were analyzed for statistical significance by
using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA). Individual data points were compared by applying a two-sided Student t test, and
P values of less than 0.05 were considered statistically significant.

RESULTS

JNK, ERK, and p38 MAPK activation in malignant and nonneoplastic hepatocytes infected with VSV. To examine the activation
states of JNK, ERK, and p38 MAPK upon VSV infection, HCC
cells (HepG2 and Huh-7), nonneoplastic immortalized hepatocytes (PH5CH8), and primary human hepatocytes (PHH) were
infected with rVSV-GFP, and lysates were collected at different
hours postinfection. The activation of these molecules occurs as a
result of phosphorylation; therefore, the cell lysates were analyzed
by Western blotting using phospho-specific antibodies to each of
these proteins. JNK activation levels increased over time and
peaked at different time points, depending on the cell type (Fig.
1A). In Huh-7 cells, the level of JNK activation was at its highest at
6 hpi and remained high until 12 hpi. In HepG2 and PH5CH8
cells, we observed a gradual increase of the level of the phosphorylated JNK form up to 12 hpi. However, in PHH, JNK activation
was not significant, and only a slight increase at the final time
point was detected. The levels of phosphorylated ERK in HCC cell
lines showed a minimal increment at around 4 to 6 hpi but remained unchanged (in Huh-7 cells) or decreased at later time
points. In contrast, p38 MAPK showed a delayed activation, occurring at 12 hpi. In HCC cells, the phosphorylation of JNK is a
fairly late event during VSV infection, which starts at around 4
hpi, coincident with VSV glycoprotein (VSV-G) expression. Infection with a UV-inactivated virus did not induce JNK activation
(data not shown).
To determine if JNK activity is necessary for the efficient replication of VSV in cell cultures, the effect of the JNK inhibitor
(JNKi) SP600125 was compared to those of the ERK inhibitor
(ERKi) and the p38 MAPK inhibitor (p38i). First, cells were pretreated with various chemical inhibitors and, in the presence of
fresh inhibitors, infected with rVSV-GFP. VSV growth was significantly reduced only in the presence of JNKi, and attenuation was
observed for all cell types (Fig. 1B). Western blotting for phosphoJNK indicated that the JNK inhibitor specifically reduced JNK
phosphorylation in VSV-infected HCC cells without interfering
with ERK activation (data not shown). In PHH, the inhibitory
effect was not as pronounced, and additionally, ERK appeared to
be affected. Nevertheless, ERK dephosphorylation was already
present in VSV-infected cultures not treated with the JNK inhibitor. Thus, our results show that in contrast to JNK, the inhibition
of ERK and p38 MAPK by their specific inhibitors did not influence VSV replication.
In addition, an siRNA-mediated knockdown of JNK was performed in HCC cell lines and nonneoplastic hepatocytes to confirm the specificity of SP600125. Cells were transfected with
scramble (Scr) siRNA or a pool of two different siRNAs against
JNK kinases, followed by infection with rVSV-GFP. Despite a robust decrease of JNK protein levels, viral replication was not af-
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fected, and no significant differences in titers were observed (Fig.
1C, left). To further define whether the inhibition of JNK was
associated with the SP600125-dependent attenuation of VSV
growth, HCC cells (data for HepG2 cells are shown) were transfected with either scramble or JNK-specific siRNAs (Fig. 1C,
right). Infection was carried out in the absence or presence of
SP600125, and viral titers were determined 24 h later. The effective
knockdown of the JNK protein was assessed by Western blotting.
As shown in Fig. 1C (right), in the presence of the JNK inhibitor,
both scramble siRNA- and JNK siRNA-transfected cells were
equally susceptible to SP600125, supporting the observation that
productive VSV infection does not require JNK.
Inhibitors of the MAPK signal do not sensitize HCC cells to
type I interferon. To determine the effect of the MAPK inhibitors
on type I IFN sensitivity, cells were treated with ERK, p38 MAPK,
and JNK inhibitors alone or in combination with IFN-␣/␤, followed by VSV infection, as described above. In all cell types, the
viral titers were appreciably lower in cultures treated with the
JNK inhibitor than in cultures treated with DMSO. A robust
attenuation of virion production upon combined treatment
with SP600125 and IFN-␣/␤ was observed, especially in PHH
and in PH5CH8 cells, indicating an additive effect of type I IFN
with SP600125 activity on viral replication (Fig. 2A). The inhibition of ERK and p38 MAPK did not enhance the efficacy of
IFN-␣/␤ against VSV in HCC cells (Fig. 2B and C).
SP600125 can synergistically enhance cell apoptosis in cancer cells (30, 37, 41). We excluded apoptosis as the cause of VSV
growth attenuation by SP600125, since the caspase inhibitor
benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (ZVAD-FMK) did not block the JNK inhibitor effect on viral titers,
and SP600125 did not induced apoptosis in PHH (data not
shown).
Viral transcription/translation and viral budding are not altered by SP600125. To identify the specific viral process blocked
by the JNK inhibitor, we examined the levels of viral RNA transcription in cells treated with SP600125. HepG2 cells as well as
PHH were pretreated with DMSO or SP600125 (25 M) and infected with VSV at an MOI of 1. Total RNAs from cell lysates were
harvested at different time points (0, 2, 4, and 8 hpi) and analyzed
for the presence and concentrations of genomic VSV RNA and for
nucleoprotein (N) mRNA by real-time PCR. The results show that
the inhibition of JNK did not interfere with VSV mRNA transcription (Fig. 3A) or genome replication in HCC or in PHH cells (Fig.
3B). Additionally, levels of the VSV G protein in SP600125-treated
cells were comparable to those in control samples (Fig. 3C). Furthermore, we compared the numbers of infectious viral particles
in the lysates and in the supernatants of cells treated with vehicle
(DMSO), interferon (IFN), or SP600125 (JNKi). In HCC cells
treated with SP600125, the numbers of infectious particles in the
cell lysates were comparable to that present in the corresponding
supernatants (Fig. 3D).
Virions from cells treated with SP600125 are impaired in
their infectivity. Since JNKi-treated cells produced significantly
reduced titers of infectious virus, we next wanted to examine the
molecular basis of this defect. HCC cells were mock treated or
exposed to SP600125 or IFN-␣/␤ overnight, followed by infection
with rVSV-GFP. Viral titers as well as the RNA copy numbers in
infected supernatants were measured. The number of budded viral particles was extrapolated by real-time PCR through the quantification of genomic viral RNA and compared to the correspond-
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FIG 1 Activation of MAPK signaling in VSV-infected cells. (A) HCC cell lines (HepG2 and Huh-7), nonneoplastic primary hepatocytes (PH5CH8), and primary
human hepatocytes (PHH) were infected with rVSV-GFP at an MOI of 10. The activation of JNK, ERK, and p38 MAPK was monitored at different time points
postinfection by Western blotting via the detection of phosphorylated forms of the indicated kinases. (B) HCC cells, PH5CH8 cells, and PHH were mock treated
(DMSO) or treated with SP600125 (JNKi) (25 M), U0126 (ERKi) (10 M), or SB203580 (p38i) and then infected with wild-type VSV at an MOI of 0.1 for 16
h. Error bars indicate standard deviations of data from experiments performed in triplicates. For all cell types, a statistically significant decrease of viral titers in
SP600125-treated cells was observed (ⴱ, P ⬍ 0.05; ⴱⴱ, P ⬍ 0.01). (C) HCC cells (data for Huh-7 cells are shown as representative data) and PH5CH8 cells were
transfected with scramble siRNA (Scr) or JNK-specific siRNA. (Left) At 72 h posttransfection, cells were infected with wild-type VSV at an MOI of 0.1 for 16 h,
and viral titers in the culture supernatants were determined by TCID50 analysis. To confirm the siRNA knockdown, cell lysates of parallel uninfected cultures were
subjected to Western blot analysis using an antibody specific for JNK. (Right) HepG2 cells transfected with scramble or JNK siRNAs were either left untreated or
treated with SP600125 (25 M) prior to VSV infection at an MOI of 0.1. Cell supernatants were assayed for viral yields, and total lysates were subjected to Western
blotting for JNK expression.

ing infectious viral titers in the same supernatants (Fig. 4A).
Numbers of copies of the VSV genome were slightly reduced upon
treatment with SP600125. In contrast, IFN-␣/␤ treatment also
resulted in an inhibition of viral genome replication. While VSV
titers in mock- and IFN-treated cells closely reflected the genome
copy numbers, the number of infectious particles was significantly
lower than the viral genome copy numbers in the supernatants of
cells treated with SP600125, indicating that the JNKi may have
affected virus infectivity without adversely affecting overall virion
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production. To determine if the loss of infectivity is due to reduced levels of incorporation of the viral proteins into budded
virions, we examined the viral proteins in the culture supernatants
of infected cells. Partially purified VSV from equal amounts of
culture supernatants was pelleted, and levels of viral proteins in
the viral pellets were analyzed by Western blotting. For cells
treated with IFN-␣/␤, the levels of all viral proteins in the pellet
were lower than those for mock-treated cells, consistent with the
observed reduction in viral titers. Interestingly, in virus pellets
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FIG 2 Antiviral activity of type I IFN in combination with MAPK inhibitors. HCC (data for HepG2 cells are shown as representative data), PH5CH8, and PHH
cells were treated with IFN-␣/␤ (100 IU/ml) in combination with 25 M SP600125 (JNKi) (A), 10 M U0126 (ERKi) (B), and 10 M SB203580 (p38i) (C).
Treatments with single agents and DMSO were included as controls. Infection with VSV-GFP at an MOI of 0.1 was then performed for 16 h, and viral titers were
determined by TCID50 analysis. Means of data from triplicate experiments are presented, with error bars indicating the standard deviations. Significance was
determined by comparison with titers of control cultures (DMSO). ⴱ, P ⬍ 0.05; ns, nonsignificant.

from SP600125-treated cells, despite a significant reduction in
VSV titers, the amount of VSV proteins was comparable to or
higher than the levels in control cells (Fig. 4B). This result indicates that the loss of infectivity was not due to reduced levels of
incorporation of viral G or other proteins into the budded virions.
Most interestingly, the protein profile of virions produced from
cells treated with SP60025 revealed an additional major protein
band (identified as VSV-G*) of approximately 120 kDa, which
appears to be related to the G protein (see below).
Moreover, to determine if the reduction of VSV growth in cells
treated with the JNK inhibitor was due merely to differences in
viral growth kinetics and, in particular, to a delay in particle release, we performed growth kinetics analyses. HCC cells were infected with VSV in the presence of vehicle (DMSO) or SP600125.
Viral titers in the supernatants were determined at various times
postinfection. A reduction of VSV replication in the presence of
SP600125 was clearly observed during the entire duration of the
kinetic analysis (Fig. 4C).
SP600125 alters VSV-G posttranslationally and hampers its
fusogenic activity. As briefly described above, the purified virions
and cell lysates from infected cells produced a slower-migrating
band of about 120 kDa (VSV-G*), in addition to the normal G
protein band, which appeared consistently when SP600125 was
applied to the cells (Fig. 5A). This slower-migrating protein band
was detected in infected cells or culture supernatants only in the
presence of SP600125. As this additional band was specifically
recognized by the antibody against VSV-G, we considered that it
might represent a modified form of viral glycoprotein G. Addi-
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tionally, this modified protein (VSV-G*) was also incorporated
into the virions (Fig. 5A). Further studies revealed that the ectopic
expression of the G protein in plasmid-transfected cells in the
presence of JNKi also resulted in the appearance of this highermolecular-weight protein band (Fig. 5B), indicating that the presence of the inhibitor may be responsible for the appearance of
VSV-G* in virus-infected or plasmid-transfected cells. The sizes
and levels of the other viral proteins were similar in untreated
and SP600125-treated supernatants (Fig. 5C), indicating that
SP600125 specifically induced the formation of this modified G
protein. The anti-VSV antibody used in this experiment also detected the additional high-molecular-weight band. The presumptive modified viral glycoprotein (VSV-G*) was further analyzed
by mass spectrometry. The fragments obtained after limited proteolysis could be identified as VSV-G protein peptides; no cellular
proteins were consistently identified in VSV-G* preparations
from two independent experiments (Table 1).
The effects of different reducing and denaturing agents were
tested in an attempt to determine the nature of VSV-G*. Initially,
we treated VSV-G* with dithiothreitol (DTT), a strong reducing
agent, to assess the possible role of a disulfide bond in VSV-G*
stability. Semipurified viral particles obtained from SP600125treated cells were exposed to DTT prior to analysis by SDS-PAGE.
Compared to samples treated with classical Laemmli buffer, containing 5% beta-mercaptoethanol and 2% SDS, DTT did not alter
the stability or mobility of VSV-G* (Fig. 5D, left). Aliquots of
lysates were then incubated at a different acidic pH and incubated
at 4°C or preheated for 10 min at 65°C or 96°C. VSV-G* expres-
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FIG 3 Viral transcription/translation and budding are not affected by SP600125. HepG2 cells and PHH were infected with VSV-GFP, and RNA was extracted
at the indicated time points. (A and B) Viral mRNA for the N protein (A) and genome RNA (B) were quantified by real-time PCR. Data represent the means of
data from three independent experiments. (C) Expression levels of VSV-G obtained from infected HepG2 cells and PHH previously treated with SP600125
(JNKi) or interferon (IFN) or left untreated were analyzed by Western blotting. (D) HCC cells left untreated (DMSO) or treated with SP600125 (JNKi) or IFN
were infected with VSV-GFP for 16 h. Viral titers in the supernatants and corresponding cell lysates were quantified by TCID50 analysis. Results represent the
means of data from three independent experiments performed in duplicates.

sion was not affected by any of these treatments (data not shown).
Additionally, to test a potential role of strong hydrophobic interactions in the VSV-G modification, the sensitivity of VSV-G* to
urea treatment was analyzed. The exposure of SP600125-derived
virions to 8 M urea did not affect the expression levels of both
VSV-G and VSV-G*, as shown by Western blotting (Fig. 5D,
right).
To exclude the possibility that SP600125 has the potential to
cross-link the VSV glycoprotein, semipurified virions obtained
from untreated cells were subjected either to direct exposure to
SP600125 or to paraformaldehyde (PFA) (Fig. 6A). Samples were
resolved by SDS-PAGE and detected by immunoblotting using an
anti-VSV-G antibody. As shown in Fig. 6A, VSV-G could be crosslinked into species migrating at the molecular weight expected for
dimeric and trimeric forms of the glycoprotein only upon treatment with PFA. This resulted in a drastic reduction in virus infectivity. However, the virions incubated with SP600125 retained
their infectivity. Furthermore, when cells underwent pretreatment with only SP600125 and viral infection was allowed to proceed in the absence of the inhibitor, VSV growth was rescued.
VSV-G* was still detectable in the corresponding cell lysates but at
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much lower expression levels than in control samples, where infection was carried out in the constant presence of the inhibitor
(Fig. 6B).
Alterations of envelope glycosylation were shown previously to
lead to impaired virus infectivity (58). To test the hypothesis that
VSV-G* could be a hyperglycosylated form of wild-type VSV-G,
we subjected semipurified virions to PNGase F or to EndoGalNAcase digestion, and we monitored the effect by Western blot analysis. PNGase F cleaves N-oligosaccharides from the glycoprotein,
and EndoGalNAcase releases O-linked glycans instead. Both
VSV-G and VSV-G* were susceptible to PNGase F digestion,
which resulted in a shift to lower-molecular-weight proteins (Fig.
6C, left), whereas EndoGalNAcase had no effect on both protein
species despite the extended incubation time (Fig. 6C, right). Notably, the enzyme treatments failed to shift VSV-G* to the fully
deglycosylated form.
To determine if VSV-G* could compromise the functionality
of the viral glycoprotein reducing infectivity of the virions, we
assessed the ability of transfected VSV-G to induce syncytia in
the presence of SP600125. Huh-7 cells were transfected with a
plasmid encoding the VSV G protein, and at 8 h posttransfection,
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FIG 4 The JNK inhibitor SP600125 interferes with VSV infectivity. (A) Viral titers obtained from DMSO-, SP600125 (JNKi)-, and IFN-treated cells were
compared to the corresponding genome copy numbers. Infection was performed for 16 h, and viral genomic RNA in the supernatants was analyzed by real-time
PCR, whereas the viral titer was determined by TCID50 assay. Upon treatment with SP600125, the difference between viral titers and genome copy numbers was
significant (ⴱ, P ⬍ 0.05). (B) Semipurified viruses obtained from DMSO-, SP600125 (JNKi)-, and IFN-treated cell supernatants by ultracentrifugation were used
to determine VSV protein expression by Western blotting. Viral titers of the samples shown are listed at the bottom. (C) Determinations of growth kinetics on
HCC cells were performed in the presence of vehicle (DMSO) or SP600125 (JNKi). Cells were infected with VSV at an MOI of 0.1, and viral titers were
determined by TCID50 analysis at the indicated time points. Mean values and standard deviations from triplicate experiments are shown.

the cells were treated either with DMSO or with SP600125. The
extent of syncytium formation was quantified at 24 h posttransfection by using a syncytium index (SI) (Fig. 7A, left). Syncytium
formation was also visualized in transfected cells not treated
(DMSO) or treated with SP600125 (JNKi) by the staining of nuclei
with propidium iodide (Fig. 7A, right) The fusion activity of
VSV-G in the presence of the JNK inhibitor was significantly reduced. The VSV growth attenuation in HCC cells was proportional to the concentration of SP600125 (Fig. 6B). The decrease in
viral titers correlated directly with the level of expression of
VSV-G* in infected cells; at a concentration of 25 M, VSV
growth was attenuated by about 10,000- to 100,000-fold, while
VSV-G* was maximally expressed (Fig. 6C). Levels of the wildtype VSV G and M proteins remained unchanged.
DISCUSSION

VSV is an oncolytic virus, which selectively grows and kills a variety of cancer cells and shows an attenuated growth phenotype in
normal cells. VSV selectivity is achieved by exploiting molecular
defects in cancer cells, which compromise the innate antiviral defense or, on the other hand, create advantages for malignant
growth and survival (38, 45). The potent cytolytic properties of
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VSV in conjunction with its rapid replication cycle have made
VSV an extremely promising candidate for oncolytic virotherapy
(1, 31, 43, 52). Interestingly, many of the signaling pathways that
viruses use are the same ones deregulated during malignant evolution. Due to their relevance in oncogenesis, these same pathways
have become targets for anticancer drug development. Now that
oncolytic viruses are finally entering the clinic, the time has come
to take a further step forward and explore possible new application
strategies involving the most up-to-date and refined anticancer
agents. Therefore, it is reasonable to foresee the great potential of
synergistic combinations of oncolytic viruses and small cell-permeable inhibitors of protein kinases to enhance tumor killing. For
example, the various MAPK pathways (ERK1/2, JNK, and p38
MAPK) appear to be some of the most significant cellular signaling cascades in the development of several malignancies, including HCC (36, 47, 49). Therefore, the inhibition of ERK can be
useful to control the growths of several human cancers (40), while
JNK modulators are able to induce cancer cell death or sensitize
tumor cells to apoptotic stimuli (12, 41). The JNK pathway has
also been linked to cell cycle progression and antiviral responses
(3, 13, 22, 42). In addition, the MAPK pathways play an important
role in the life cycles of certain viruses (10, 19, 33, 46, 61). In view
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FIG 5 SP600125 induces a posttranslational modification of the VSV-G protein. (A) Levels of viral glycoprotein (VSV-G) from isolated viral particles (top) or
infected-cell lysates (bottom) were analyzed by Western blotting. Huh-7 cells, used as representative cells, were pretreated with SP600125 (JNKi) or with the
vehicle (DMSO) and infected with VSV at an MOI of 0.1 for 24 h. A fast-migrating band (VSV-G) was identified in all the samples and represents the mature form
of the VSV glycoprotein. When infection was performed in the presence of SP600125, a slower-migrating band (VSV-G*) was present. (B) Huh-7 cells were
transfected with an empty vector (pCR3) or with a vector expressing the VSV glycoprotein (pCMV-VSV-G). Cells were cultured for 24 h in the presence of DMSO
or SP600125 (JNKi), and cell lysates were analyzed by Western blotting using a specific anti-VSV-G antibody. (C) Western blot analysis of VSV obtained from
DMSO-treated or SP600125-treated (JNKi) cells. Levels of the VSV glycoprotein (G), phosphoprotein/nucleoprotein (P/N), and matrix protein (M) were
detected by an anti-VSV serum (kindly provided by Douglas Lyles). (D) Semipurified VSV obtained from DMSO- or SP600125-treated cultures was subjected
to DTT reduction. (Left) Lysates were treated with 10 or 50 mM DTT and loaded together with untreated controls on an SDS-PAGE gel. (Right) The same samples
were alternatively exposed to 8 M urea and analyzed by Western blotting.

of a combinatorial approach with new drugs based on the specific
targeting of MAPK and oncolytic viruses, we investigated the use
of such combinations using VSV in the context of HCC.
In this work, we have studied the influence of three of the
major MAPK inhibitors on VSV oncolysis in vitro, comparing
HCC cell lines with primary human hepatocytes. It was previously
shown that ERK facilitates VSV-mediated oncolysis by the nega-

tive regulation of the IFN-␣ response (43). In many HCC cell
lines, the innate immunity response to pathogens is compromised, especially due to multiple defects in the type I IFN system
(38). The reestablishment of a functional type I IFN response in
HCC would be seriously detrimental to the therapeutic efficacy of
VSV. Our studies demonstrated that in HCC cell lines, the activation of the ERK signaling pathway does not enhance VSV oncol-

TABLE 1 Identification of SP600125-induced high-molecular-mass VSV-G* by MS
Positions of fragment

Expected mass (kDa)

Measured mass (kDa)

⌬ mass

No. of misses

Sequence

1–11
16–44
51–63
84–100
175–200
207–217
231–249
250–277
278–290
293–308
333–342
343–354
355–375
382–401
402–432
433–446
483–492

1,357.84
3,328.6
1,489.70
1,996.93
2,834.21
1,235.50
2,123.14
3,033.54
1,641.85
1,639.91
1,053.55
1,313.58
2,472.19
2,292.10
3,398.62
1,690.87
1,297.53

1,357.75
3,328.56
1,489.64
1,996.94
2,834.30
1,235.55
2,123.05
3,033.42
1,641.77
1,639.91
1,053.62
1,313.60
2,472.16
292.09
3,398.61
1,690.84
1,297.60

0.09
0.04
0.05
⫺0.01
⫺0.09
⫺0.05
0.09
0.12
0.08
⫺0.01
⫺0.07
⫺0.01
0.04
0.01
0.01
0.03
⫺0.07

1
0
0
1
0
0
1
0
0
0
0
0
0
0
0
0
0

KFTIVFPHNQK
NVPSNYHYCPSSSDLNWHNDLIGTAIQVK
AIQADGWMCHASK
SFTPSVEQCKESIEQTK
GLCDSNLISMDITFFSEDGELSSLGK
SNYFAYETGGK
LPSGVWFEMADKDLFAAAR
FPECPEGSSISAPSQTSVDVSLIQDVER
ILDYSLCQETWSK
AGLPISPVDLSYLAPK
VDIAAPILSR
MVGMISGTTTER
ELWDDWAPYEDVEIGPNGVLR
FPLYMIGHGMLDSDLHLSSK
AQVFEHPHIQDAASQLPDDESLFFGDTGLSK
NPIELVEGWFSSWK
QIYTDIEMNR
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FIG 6 VSV-G* is not the result of cross-linking or hyperglycosylation processes. (A) Semipurified virions were exposed to increasing concentrations of SP600125
(JNKi) for 1 h on ice. As a control, virions were cross-linked with PFA (2%) on ice for 15 min. One-tenth of the samples was preheated at 56°C for 10 min and
loaded onto an SDS-PAGE gel. Viral glycoprotein monomers (G), dimers (G2), and trimers (G3) were detected with a polyclonal antibody specific for VSV-G
(bottom). The same samples were used to infect HepG2 cells, and viral progeny was quantified by TCID50 analysis at 24 h postinfection. (B) Huh-7 cells were
pretreated with SP600125 and infected with VSV-GFP at an MOI of 1. Infection was carried out without or in the presence of the inhibitor SP600125 for 24 h.
DMSO-treated cells were used as a control. Viral titers and levels of VSV-G and VSV-G* in the corresponding cell lysates are shown and represent the means of
data from three independent experiments. (C) Semipurified virions obtained in the presence or absence of SP600125 were digested with PNGase F (left) or
EndoGalNAcase (right) overnight. After digestion, the expression levels of VSV-G and VSV-G* were analyzed by Western blotting.

ysis, since protection from lytic infection was not improved by the
coadministration of the ERK inhibitor U0126 and IFN-␣/␤.
Therefore, the disruption of ERK signaling by anticancer drugs
seems to be compatible with VSV therapy in HCC, at least in vitro.
The discrepancy of our results compared with those of previous
reports (43) emphasizes the need to consider each cancer type as a
unique environment. For this reason, preliminary in vitro studies
assume a great significance in view of subsequent clinical investigations.
Since their discovery in the early 1990s, JNKs have attracted
intense interest due to the increasing evidence of the involvement
of JNK-dependent signaling events in the development of several
pathological conditions. The potential therapeutic application of
JNK-specific inhibitors for the treatment of different human diseases, from ischemia, diabetes, and cancer to viral infectious diseases, has been explored (25, 34, 39). Notably, JNK1 has an essential oncogenic role in HCC development, and direct evidence
comes from in vivo studies with JNK1 knockout mice. In mice
lacking JNK1, diethylnitrosamine-triggered liver tumorigenesis
was remarkably reduced, and treatment with chemical JNK inhibitors resulted in the reduced growth of xenografted human HCC
cells (22, 42). Besides SP600125 (3), several small-molecule compounds inhibiting JNK kinase activity with higher selectivity and
efficacy have been developed (35), and the combination of these
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new inhibitors with VSV virotherapy could potentially be beneficial for HCC treatment.
Increasingly, it has been shown that viral infection can lead to
stress-activating protein kinase (SAPK)/JNK and p38 MAPK activation, which is needed for viral replication and release (21, 39, 54,
61). In this report, we observed a strong activation of JNK upon
the infection of HCC cell lines with VSV, while the levels of activation of ERK and p38 MAPK were very weak. Inhibitors of p38
MAPK (SB203580) and of ERK (U0126) did not reduce the viral
yield in HCC cells. On the other hand, the JNK inhibitor SP600125
dramatically decreased viral titers in all cell types tested, consistent
with previous studies with dengue virus, rotavirus, and circovirus
(7, 19, 56). SP600125 and other similar anthrapyrazoles are considered to be valuable therapeutic agents; their usefulness against
cancer (3, 15), liver injury, and fibrosis (20, 29) has been associated with minimal toxicity in vivo. Unfortunately, in light of our
results, we excluded the possibility of a conjunctive application of
SP600125 and VSV therapy. However, our results indicate that the
attenuation of VSV by SP600125 is due to a nonspecific mechanism that does not involve the inhibition of JNK, and therefore,
the combination of VSV and other specific JNK inhibitors still
represents a viable treatment option.
Most interestingly, despite the fact that the numbers of copies
of the viral genome in the supernatants of SP600125-treated cells
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FIG 7 SP600125 decreases the fusion activity of VSV-G. (A) Huh-7 cells were transfected with an expression vector for the VSV glycoprotein (pCMV-VSV-G).
At 8 h posttransfection, supernatants were replaced with fresh medium containing either DMSO or SP600125 (25 M). Syncytium formation was quantified by
the determination of the syncytium index (SI) (Fig. 6A, left), and parallel cultures were fixed and stained with propidium iodide (PI) to visualize syncytia (Fig.
6A, right). ⴱⴱ, P ⬍ 0.01. (B) HCC cells were treated with increasing concentrations of SP600125 and infected with VSV at an MOI of 0.1 for 24 h. Aliquots
of the supernatants were subjected to TCID50 assay for determination of viral titers. Means and standard deviations of data from duplicate experiments are
shown. (C) Expression levels of VSV-G and VSV-G* were analyzed by Western blotting in the corresponding cell lysates (data for HepG2 cells are shown as
representative data). The maximum expression level of VSV-G* was at 25 M SP600125, the concentration which corresponds to the greatest attenuation of VSV.

did not differ substantially from those in the untreated controls,
the infectious viral titers were significantly lower, up to 10,000- to
100,000-fold. These results led us to conclude that SP600125 affects VSV infectivity such that only a fraction of the new viral
progeny released into the culture supernatant retains the ability to
reinfect cells. As a cause of a lack of infectivity of newly formed
virions, we have found that the viral particles incorporate at least
two different forms of the G protein in the presence of SP600125:
one that comigrates with the normal G protein and the other that
is significantly higher in molecular mass than the normal G protein (VSV-G*). The same result was observed when a VSV-G protein-expressing plasmid was transfected in the presence of the JNK
inhibitor.
At this point, we speculated that VSV-G* could represent either a hyperglycosylated form of VSV-G or a VSV-G dimer, since
the size was roughly twice the size of the monomeric G protein. An
alteration of glycosylation can have a dramatic impact on the infectivity of viruses; as observed previously by Whitt and colleagues, virions incorporating a glycoprotein with an additional
N-linked oligosaccharide in the extracellular domain were not
infectious, apparently due to the formation of heterodimers that
lacked fusion activity (58). In our experiments, digestion with Nor O-glycosidases did not completely abolish VSV-G* expression,
leading us to the conclusion that this form was not assignable to a
hyperglycosylated status (Fig. 6C). Intriguingly, VSV-G* may represent a protein complex or an as-yet-unknown modification of
the G protein that is thermostable and resistant to SDS; additionally, it does not dissociate under reducing conditions (DTT) and is
not denatured by urea. Moreover, exposure to an acidic pH at an
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elevated temperature did not to affect the detection of VSV-G*
(data not shown).
The incubation of extracellular VSV with SP600125 did not
lead to VSV-G* formation, nor did it hamper viral infectivity,
ruling out a possible cross-linking activity of SP600125. Pretreatment alone with infection carried out in the absence of SP600125
resulted in reduced levels of VSV-G* and a partial recovery of viral
titers.
Mass spectrometry analysis revealed that VSV-G* contains
only peptides from the VSV G protein. In repeated experiments,
we did not identify any cellular protein consistently in VSV-G*
preparations, including the ones related to major posttranslational modifications, such as ubiquitination, sumoylation, neddylation, and ISGylation, etc. (23, 27, 50, 55, 59). Despite the fact that
we were able to exclude several mechanisms involved in protein
modifications, the nature of VSV-G* still remains enigmatic, yet it
is possible that unidentified modifications through covalent linkages are responsible for the formation of VSV-G*. Given the difficulty in identifying these processes, further studies will be required to address this important aspect.
The presence of VSV-G* species compromised the fusion activity of the VSV glycoprotein; in the presence of SP600125, the
expression of VSV-G* led to a reduction in levels of syncytium
formation. Since increased levels of VSV-G* expression depend
on the SP600125 concentration and correlate inversely with viral
titers, we postulate that SP600115 attenuates VSV by hampering
the VSV glycoprotein fusogenic activity.
In conclusion, our in vitro results support the concept that
combination therapy using oncolytic VSV and MAPK inhibitors
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might result in synergistic antitumor activity against HCC, and we
plan to test this hypothesis in future in vivo studies. Furthermore,
at the molecular level, we have provided new insights into the
antiviral properties of the inhibitor SP600125. SP600125 also attenuates the growths of several viruses of different families, suggesting a possible common mechanism of action that could be
exploited for the development of antiviral treatment. A very intriguing application of SP600125 could be as a treatment of viral
infections that are accompanied by malignant transformation.
Both antiviral and antitumor effects of the drug could have significant benefits, for example, in the treatment of hepatitis C virus or
human papillomavirus infection (16, 60). The elucidation of viral
posttranslational control and viral mechanisms of infectivity can
also be investigated by means of the effect of SP600125 on VSV-G
maturation, leading to the development of new and targeted antiviral strategies.
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